ABUS Stock Overview
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States.
Arbutus Biopharma Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.48|
|52 Week High||US$6.50|
|52 Week Low||US$1.93|
|1 Month Change||-2.36%|
|3 Month Change||7.36%|
|1 Year Change||-25.30%|
|3 Year Change||69.86%|
|5 Year Change||-32.97%|
|Change since IPO||-64.77%|
Recent News & Updates
Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...
Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Arbutus Biopharma (NASDAQ:ABUS) on Wednesday said its phase 2a hepatitis B virus infection trial with partner Assembly Biosciences (ASMB) evaluating a combination involving drug candidates by both companies would continue, despite ASMB's decision to stop development of its product. ASMB in a separate release said that it would end development of its inhibitor vebicorvir. But ABUS and ASMB, after consultation, plan to continue their phase 2a trial investigating a combination of ABUS' RNAi therapeutic AB-729, ASMB's vebicorvir and an inhibitor therapy for the treatment of chronic hepatitis B virus infection. “While we respect Assembly’s decision to discontinue clinical development of (vebicorvir), we believe that it is premature to make any conclusions about any results in this triple combination clinical trial," said ABUS CEO William Collier. "We intend, in collaboration with Assembly, to continue the clinical trial in order to fully and accurately assess the results," Collier added. ABUS said preliminary data from the mid-stage trial is expected in H2 of this year. Arbutus (ABUS) stock was up 3.1% to $2.65 after hours.
|ABUS||US Biotechs||US Market|
Return vs Industry: ABUS underperformed the US Biotechs industry which returned -19.6% over the past year.
Return vs Market: ABUS underperformed the US Market which returned -9.6% over the past year.
|ABUS Average Weekly Movement||8.4%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: ABUS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ABUS's weekly volatility (8%) has been stable over the past year.
About the Company
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
Arbutus Biopharma Corporation Fundamentals Summary
|ABUS fundamental statistics|
Is ABUS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABUS income statement (TTM)|
|Cost of Revenue||US$77.33m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.51|
|Net Profit Margin||-228.05%|
How did ABUS perform over the long term?See historical performance and comparison